Magnetic relaxation in tissues can be enhanced using contrast agents. The most commonly used for MRI are the paramagnetic contrast agents, which have their strongest effect on the T1, by increasing T1 signal intensity in tissues where they have accumulated.
MRI collects signal from the water protons, but the presence of these contrast agents enhances the relaxation of water protons in their vicinity. Paramagnetic contrast agents contain magnetic centers that create magnetic fields approximately one thousand times stronger than those corresponding to water protons. These magnetic centers interact with water protons in exactly the same way as the neighboring protons, but with much stronger magnetic fields, and therefore, have a much greater impact on relaxation rates, particularly on T1. In MRI, contrast agents are routinely injected intravenously to help identify areas of hypervascularity, as in malignant tumors.

See also Contrast Agents, Gadovist®, MultiHance®, Omniscan®, OptiMARK®.

See also the related poll result: 'The development of contrast agents in MRI is'

The phase angle f is in turn affected by resonance offsets due to magnetic field inhomogeneity. If f varies throughout the image, the result will be inhomogeneous signal intensity (shading).

(PCA) With this method images of the blood flow-velocity (or any other movement of tissue) are produced. The MRI signal contains both amplitude and phase information. The phase information can be used with subtraction of images with and without a velocity encoding gradient. The signal will be directly proportional to the velocity because of the relation between blood flow-velocity and signal intensity.
This is the strength of PCA, complete suppression of stationary tissue (no velocity - no signal), the direct velocity of flow is being imaged, while in TOF (Inflow) angiography, tissue with short T1 (fat or methaemoglobin) might be visualized.
The strength of the gradient determines the sensitivity to flow. It is set by setting the aliasing or encoding velocity (VENC). Unfortunately, phase sensitization can only be acquired along one axis at a time. Therefore, phase contrast angiographic techniques tend to be 4 times slower than TOF techniques with the same matrix.

See also Phase Contrast Sequence, Magnetic Resonance Angiography, Contrast Enhanced Magnetic Resonance Angiography, Flow Effects and Flow Quantification.

(PC) Phase contrast sequences are the basis of MRA techniques utilizing the change in the phase shifts of the flowing protons in the region of interest to create an image. Spins that are moving along the direction of a magnetic field gradient receive a phase shift proportional to their velocity.
In a phase contrast sequence two data sets with a different amount of flow sensitivity are acquired. This is usually accomplished by applying gradient pairs, which sequentially dephase and then rephase spins during the sequence. Both 2D and 3D acquisition techniques can be applied with phase contrast MRA.
The first data set is acquired with a flow compensated sequence, i. e. without flow sensitivity. The second data set is acquired with a flow sensitive sequence. The amount of flow sensitivity is controlled by the strength of the bipolar gradient pulse pair, which is incorporated into the sequence. Stationary tissue undergoes no effective phase change after the application of the two gradients. Caused by the different spatial localization of flowing blood to stationary tissue, it experiences a different size of the second bipolar gradient compared to the first. The result is a phase shift.
The raw data from the two data sets are subtracted. By comparing the phase of signals from each location in the two sequences the exact amount of motion induced phase change can be determined to have a map where pixel brightness is proportional to spatial velocity.
Phase contrast images represent the signal intensity of the velocity of spins at each point within the field of view. Regions that are stationary remain black while moving regions are represented as grey to white.
The phase shift is proportional to the spin's velocity, and this allows the quantitative assessment of flow velocities. The difference MRI signal has a maximum value for opposite directions. This velocity is typically referred to as venc, and depends on the pulse amplitude and distance between the gradient pulse pair. For velocities larger than venc the difference signal is decreased constantly until it gets zero. Therefore, in a phase contrast angiography it is important to correctly set the venc of the sequence to the maximum flow velocity which is expected during the measurement. High venc factors of the PC angiogram (more than 40 cm/sec) will selectively image the arteries (PCA - arteriography), whereas a venc factor of 20 cm/sec will perform the veins and sinuses (PCV or MRV - venography).

See also Flow Quantification, Contrast Enhanced MR Venography, Time of Flight Angiography, Time Resolved Imaging of Contrast Kinetics.

Primovist™ (U.S brand name Eovist®) is a highly specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans.
Primovist™ brightens the signal of T1 weighted MR images immediately after contrast administration. Dynamic scanning and imaging of the accumulation phase (best after 20 min.) can also be performed after bolus injection of Primovistâ„¢. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered.

WARNING: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.